about
Risk factors for intra-abdominal hypertension and abdominal compartment syndrome among adult intensive care unit patients: a systematic review and meta-analysisActive Negative Pressure Peritoneal Therapy After Abbreviated Laparotomy: The Intraperitoneal Vacuum Randomized Controlled Trial.A Survey of Rounding Practices in Canadian Adult Intensive Care UnitsIntraventricular fibrinolysis with tissue plasminogen activator is associated with transient cerebrospinal fluid inflammation: a randomized controlled trial.Use and Utility of Administrative Health Data for Stroke Research and Surveillance.History, Evolution, and Importance of Emergency Endovascular Treatment of Acute Ischemic Stroke.Improving Door-to-Needle Times for Acute Ischemic Stroke: Effect of Rapid Patient Registration, Moving Directly to Computed Tomography, and Giving Alteplase at the Computed Tomography Scanner.Multiphase CT angiography increases detection of anterior circulation intracranial occlusion.Drip 'n Ship Versus Mothership for Endovascular Treatment: Modeling the Best Transportation Options for Optimal Outcomes.Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain.Workflow in Acute Stroke: What Is the 90th Percentile?Drip and Ship Versus Direct to Comprehensive Stroke Center: Conditional Probability Modeling.Intraventricular tissue plasminogen activator in subarachnoid hemorrhage patients: a prospective, randomized, placebo-controlled pilot trial.Drip and ship versus direct to endovascular thrombectomy: The impact of treatment times on transport decision-makingModeling Stroke Patient Transport for All Patients With Suspected Large-Vessel OcclusionVariations in Modeling for Treating Acute Stroke-ReplyDistribution and current problems of acute endovascular therapy for large artery occlusion from a two-year national survey in JapanOrganizing stroke systems in the field for patients with suspected large vessel occlusion acute stroke
P50
Q26864634-116D8C1A-96E1-4386-A274-6CEB21EF6C8AQ35718469-5667C5C3-C723-42B2-AF67-67555FB8D1C7Q35877696-59EB3062-C56B-4DFA-A2BA-AF6657856FE7Q35925444-33CF7F1C-6FBA-49B9-AFCA-B424E7A7EB8AQ36016494-8B6044ED-B57C-4CFD-9467-2B43F98E698EQ38791820-3E133F01-FCFA-43CB-B4AE-0AAA044A392BQ39016227-A64A58A4-ECDF-4E81-88A6-AEB0CCC86B7FQ41844588-16ECBA66-61E5-4440-B79E-64C4E8255312Q48006559-55074907-3E0F-4A9E-B158-9C3E38D0D098Q48297673-BC4C6231-CCC7-4B66-B5CE-61E6C10F8388Q48310807-30DC7ABC-3893-498E-B97E-8D6913240245Q48412590-48A536C9-5424-42B6-ABB0-899D8F9EB1F1Q51102181-5A4EF3C7-45F1-4DD5-890D-E1BEA5EA6934Q90118212-4A413A17-3323-4EF2-9D17-3299E87DA4B1Q91332790-4D55617E-7064-4830-8247-521464A67A8CQ92595254-E41A8456-A082-4A62-927E-4C4F8B341736Q92598414-37A11F5F-6462-43E2-8440-6FD437A8DF77Q93207401-E653EFAD-2518-494A-A3E7-1E330C59E46C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jessalyn K Holodinsky
@en
Jessalyn K Holodinsky
@nl
type
label
Jessalyn K Holodinsky
@en
Jessalyn K Holodinsky
@nl
prefLabel
Jessalyn K Holodinsky
@en
Jessalyn K Holodinsky
@nl
P31
P496
0000-0003-1748-5211